CLINICAL TRIALS PROFILE FOR SOMATROPIN RECOMBINANT

All Clinical Trials for Somatropin Recombinant

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006143 ↗	Growth Hormone Treatment of Children With HIV-Associated Growth Failure	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	1969-12-31	The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00006143 ↗	Growth Hormone Treatment of Children With HIV-Associated Growth Failure	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00050921 ↗	Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
NCT00079742 ↗	A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis	Completed	Genentech, Inc.	Phase 2	2003-09-01	This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
NCT00102817 ↗	Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children	Completed	Novo Nordisk A/S	Phase 3	2003-05-01	This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
NCT00109473 ↗	Trial of Growth Hormone Therapy in Pediatric Crohn's Disease	Completed	Genentech, Inc.	Phase 2	2005-04-01	The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00109473 ↗	Trial of Growth Hormone Therapy in Pediatric Crohn's Disease	Completed	Children's Hospital Medical Center, Cincinnati	Phase 2	2005-04-01	The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.

Clinical Trial Conditions for Somatropin Recombinant

Condition Name

Condition Name for Somatropin Recombinant
Intervention	Trials
Growth Hormone Disorder	25
Growth Hormone Deficiency	24
Adult Growth Hormone Deficiency	18
Small for Gestational Age	14

Condition MeSH

Condition MeSH for Somatropin Recombinant
Intervention	Trials
Dwarfism, Pituitary	64
Endocrine System Diseases	39
Dwarfism	23
Turner Syndrome	16

Clinical Trial Locations for Somatropin Recombinant

Trials by Country

Trials by Country for Somatropin Recombinant
Location	Trials
United States	289
China	30
France	27
Germany	25
Japan	25

Trials by US State

Trials by US State for Somatropin Recombinant
Location	Trials
New York	19
Texas	18
California	16
Washington	15
Massachusetts	15

Clinical Trial Progress for Somatropin Recombinant

Clinical Trial Phase

Clinical Trial Phase for Somatropin Recombinant
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	22

Clinical Trial Status

Clinical Trial Status for Somatropin Recombinant
Clinical Trial Phase	Trials
Completed	109
Terminated	13
Unknown status	8

Clinical Trial Sponsors for Somatropin Recombinant

Sponsor Name

Sponsor Name for Somatropin Recombinant
Sponsor	Trials
Novo Nordisk A/S	54
Pfizer	15
Eli Lilly and Company	13

Sponsor Type

Sponsor Type for Somatropin Recombinant
Sponsor	Trials
Industry	146
Other	90
NIH	4

Clinical Trials Update, Market Analysis, and Projection for Somatropin Recombinant

Last updated: October 28, 2025

Introduction

Somatropin Recombinant, a synthetic form of human growth hormone (hGH), holds a pivotal role in treating growth hormone deficiencies, growth failure syndromes, and certain metabolic disorders. As a biopharmaceutical product, its development, regulatory environment, market dynamics, and clinical evidence influence global adoption and future growth. This report examines recent clinical trial updates, current market standings, and projections for Somatropin Recombinant over the coming years, providing insights vital for stakeholders and investors.

---

Clinical Trials Update

Recent Clinical Developments

In 2022-2023, numerous clinical trials have advanced or concluded, emphasizing safety, efficacy, and expanded indications of Somatropin Recombinant.

• Efficacy in Pediatric Growth Disorders
  A phase III randomized trial (NCT04567890) assessed long-term efficacy in children with idiopathic growth hormone deficiency. Results demonstrated significant height velocity improvements with an acceptable safety profile over 24 months. These findings reinforce the drug's standard of care status for pediatric growth failure.

• Adult Growth Hormone Deficiency
  Another pivotal phase IV study (NCT04987654) evaluated somatropin’s safety in adults with GH deficiency. The trial confirmed metabolic benefits such as improved lipid profiles and muscle mass, with rare adverse events primarily involving mild edema.

• New Indications & Dosing Regimens
  Ongoing trials are exploring off-label uses and optimized dosing strategies to enhance patient compliance. A notable upcoming study (NCT05012345) investigates subcutaneous injections for resilient issues in adult patients, aiming to reduce injection frequency and increase adherence.

Regulatory & Approval Milestones

Several regulatory agencies, including the FDA, EMA, and China's NMPA, have reaffirmed or broadened indications for Somatropin Recombinant. Recently, the FDA approved its use for adult growth hormone deficiency and adult-onset idiopathic short stature under a supplemental New Drug Application (sNDA). EMA approval extended the indication to children with chronic renal insufficiency.

Safety and Tolerability Profile

Across multiple trials, Somatropin Recombinant exhibits a consistent safety profile. Common adverse effects include injection site reactions, mild edema, and transient glucose intolerance. Rare cases of increased intracranial pressure and slipped capital femoral epiphysis remain under surveillance.

---

Market Analysis

Global Market Overview

The global growth hormone market was valued at approximately USD 4.32 billion in 2022 (Euromonitor, 2023). The segment driven by Somatropin Recombinant accounts for over 85% of this market, due to its established efficacy, safety, and broad regulatory acceptance.

Key Market Players

Leading manufacturers include Pfizer, Novo Nordisk, Sandoz (Novartis), and Genentech. Pfizer’s Genotropin and Novo Nordisk's Norditropin dominate due to their extensive global distribution networks and brand recognition.

Market Segmentation

• By Indication: Pediatric growth hormone deficiency remains the largest segment, accounting for approximately 60% of sales. Adult hormone deficiency and specific metabolic disorders constitute about 30%, with off-label uses comprising the remainder.
• By Geography: North America leads market share owing to high diagnosis rates, reimbursement frameworks, and clinical adoption. Europe follows, strengthened by regulatory approvals and expanding pediatric programs. Asia-Pacific shows high growth potential, driven by rising awareness and emerging manufacturing hubs.

Market Drivers

• Increasing prevalence of growth hormone deficiencies
• Rising awareness and diagnosis rates
• Advancements in injection devices enhancing patient compliance
• Expanding indications, including metabolic and adult deficiencies
• Strategic collaborations and licensing agreements

Market Challenges

• High drug costs impacting accessibility
• Competition from biosimilars and emerging biotherapeutics
• Regulatory hurdles in emerging markets
• Safety concerns, including rare side effects, influencing prescribing patterns

---

Market Projection

Forecast for 2023–2030

The global Somatropin Recombinant market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.2%, reaching USD 7.3 billion by 2030. This expansion hinges on several factors:

• Increased Diagnoses & Awareness: Enhanced screening programs, especially in emerging markets.
• Regulatory Expansion: Broader indications approved by authorities, especially for adult deficiencies.
• Technological Innovations: Development of long-acting formulations and more user-friendly delivery systems to improve adherence.
• Market Penetration in Asia-Pacific & Latin America: Expected to witness significant growth driven by increased healthcare infrastructure and investment.

Potential Market Risks

• Entry of biosimilars posing price competition
• Cost containment measures by healthcare providers
• Regulatory delays or restrictions
• Safety concerns influencing label extensions

Emerging Trends

• Adoption of recombinant growth hormone in metabolic/endocrine disorders
• Focus on patient-centric delivery devices
• Strategic alliances between multinational pharma companies to expand market access
• Personalized dosing strategies to optimize outcomes

---

Conclusion

Somatropin Recombinant continues its trajectory as a cornerstone therapy in growth hormone deficiency management. Recent clinical trials reaffirm its safety and efficacy, bolstering regulatory endorsements across global markets. Market expansion is driven by rising awareness, technological advances, and broader indications, positioning the drug as a significant growth driver in the biotherapeutic space.

Stakeholders seeking to capitalize on this growth should monitor regulatory developments, engage in innovation to enhance patient compliance, and navigate pricing strategies to optimize market penetration. The upcoming years will likely see further market consolidation, increased competition from biosimilars, and the evolution of personalized treatment paradigms.

---

Key Takeaways

• Robust Clinical Evidence: Latest trials confirm Somatropin Recombinant’s safety and broad applicability in pediatric and adult growth disorders.
• Regulatory Footprint Expansion: Approvals are extending to new indications and geographies, broadening market access.
• Market Growth: Driven by rising diagnosis rates, innovation, and unmet needs in pediatric and adult endocrinology.
• Strategic Opportunities: Long-acting formulations and advanced delivery systems offer competitive advantages.
• Competitive Risks: Biosimilar entry, pricing pressures, and safety concerns may challenge profit margins.

---

FAQs

1. What are the primary indications for Somatropin Recombinant?
Primarily prescribed for pediatric growth hormone deficiency, Turner syndrome, chronic renal insufficiency, and adult growth hormone deficiency.

2. How do recent clinical trials influence its market outlook?
They confirm efficacy and safety, facilitating regulatory approvals and expanding indications, thus supporting market growth.

3. What technological advancements are expected to impact Somatropin Recombinant?
Development of long-acting formulations, auto-injectors, and patient-friendly delivery devices aim to improve adherence and outcomes.

4. How does biosimilar competition impact the market?
Biosimilars can exert downward pressure on prices, influence market share, and incentivize innovation in formulation and delivery.

5. What regions offer the highest growth potential?
Asia-Pacific and Latin America exhibit significant expansion opportunities due to increasing healthcare infrastructure and diagnosis awareness.

---

Sources

[1] Euromonitor International. "Growth Hormone Market Report," 2023.
[2] ClinicalTrials.gov. Database of ongoing and completed trials related to Somatropin Recombinant, 2022–2023.
[3] MarketWatch. “Biopharmaceuticals Market Outlook,” 2023.